Welcome to our dedicated page for INVVY news (Ticker: INVVY), a resource for investors and traders seeking the latest updates and insights on INVVY stock.
Indivior PLC (LSE/Nasdaq: INDV) is a global pharmaceutical company dedicated to developing medicines to treat substance use disorders (SUD) and serious mental illnesses. With a vision to provide evidence-based treatments for chronic conditions worldwide, Indivior is focused on transforming SUD into a recognized and treated chronic disease. Headquartered in Richmond, VA, Indivior's portfolio of products is available in 37 countries, with a pipeline of product candidates aiming to address various chronic conditions and co-occurring disorders of SUD.
Indivior PLC reported its financial results for the first quarter of 2023, ending March 31, 2023. The earnings release, along with an investor presentation and a live webcast, is available on the company’s website.
Indivior aims to transform substance use disorders (SUD) into treated chronic diseases by leveraging its global portfolio of opioid use disorder treatments. The company employs over 1,000 people and operates across 39 countries, underscoring its commitment to providing evidence-based treatment options.
For more details, access the earnings release and investor presentation via the provided links.
Indivior PLC (LSE: INDV) has announced its participation in the Bank of America Global Healthcare Conference 2023, taking place in Las Vegas on May 10 and 11. CEO Mark Crossley will conduct 1x1/group meetings and present on May 10 at 5:00 p.m. PDT (8:00 p.m. EST). Interested investors can contact their Bank of America representative to schedule meetings. The presentation will be accessible through www.indivior.com and via a webcast link. Indivior is dedicated to developing treatments for substance use disorders (SUD) and serious mental illnesses, aiming to provide global access to evidence-based treatment for these chronic conditions. The company is headquartered in Richmond, VA, and has operations in 39 countries worldwide.
Indivior PLC has completed its acquisition of Opiant Pharmaceuticals, strengthening its addiction treatment portfolio. The acquisition, valued at approximately $145 million, includes an upfront payment of $20 per share for Opiant's stock, with additional contingent value rights that could reach $8 per share based on revenue milestones from Opiant's investigational drug OPNT003. This drug targets opioid overdose, with peak projected revenues of $150 million to $250 million after its anticipated FDA approval on May 22, 2023. Indivior expects to provide updated fiscal guidance on April 27, 2023.
Indivior PLC (LSE: INDV) announced its 2022 Full Year Results on February 16, 2023. The company aims to transform substance use disorders into recognized chronic diseases by providing evidence-based treatment worldwide. Indivior's product portfolio is available in 39 countries and includes treatments for opioid use disorders. Investors can access detailed earnings results, presentations, and webcasts on the company’s official website. The full earnings release can be found here.
FAQ
What is the market cap of INVVY (INVVY)?
What does Indivior PLC specialize in?
Where is Indivior PLC headquartered?
How many countries is Indivior's portfolio of products available in?
What is Indivior's vision for patients around the world?
What is the focus of Indivior's global portfolio?
